Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01882829 · ClinicalTrials.gov registry record · Phase 2
Nuedexta in Treatment-Resistant Major Depression
A Phase 2 study, sponsored by James Murrough.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01882829 is a Phase 2 study that has completed, run by James Murrough. The registered enrollment target is 20 participants.
The verdict
NCT01882829, a Phase 2 study, has completed, sponsored by James Murrough.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
There is an urgent need, therefore, to identify well-tolerated, orally available compounds that target the NMDA receptor as a novel treatment approach for TRD. The current project aims to test the safety, tolerability and efficacy of Nuedexta - containing the NMDA antagonist dextromethorphan.
Interventions
- DRUG dextromethorphan/quinidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-07 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01882829
The ClinicalTrials.gov registry entry for NCT01882829 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is James Murrough, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dextromethorphan/quinidine is the first listed.
NCT01882829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01882829 about?
NCT01882829 is a clinical study titled "Nuedexta in Treatment-Resistant Major Depression". There is an urgent need, therefore, to identify well-tolerated, orally available compounds that target the NMDA receptor as a novel treatment approach for TRD. The current project aims to test the safety, tolerability and efficacy of Nuedexta - containing the NMDA antagonist dextromethorphan.
What is the current status of trial NCT01882829?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2013-07. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01882829?
The interventions under investigation include: dextromethorphan/quinidine (DRUG).
Who is sponsoring clinical trial NCT01882829?
This trial is sponsored by James Murrough, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.